Navigation Links
Fate Therapeutics to Present Data on Stimulation of Osteogenic Activity Using Small Molecule Modulators of Wnt Pathway

LA JOLLA, Calif., and BARCELONA, July 8 /PRNewswire/ -- Fate Therapeutics, Inc. announced today the presentation of data from its research on small molecule modulators of the Wnt pathway for osteo-regeneration at the 7th Annual Meeting of the International Society for Stem Cell Research (ISSCR) in Barcelona, Spain. In its findings, the Company demonstrated that selected Wnt activators induce the differentiation of mesenchymal stem cells to mature, bone-forming osteoblasts. The study highlights the potential for using small molecule Wnt activators as osteogenic agents. Because osteogenic agents stimulate positive bone growth, they may offer an improved course of action in clinical settings ranging from orthopedics to osteoporosis as compared to current medications aimed at preventing bone decay.

"By applying our knowledge of adult stem cell biology to mesenchymal stem cell populations, we have identified osteogenic small molecules that can direct lineage-specific differentiation to an osteoblast phenotype," said Paul Grayson, president and CEO of Fate Therapeutics. "While current therapies focus on blocking bone degeneration, novel small molecules that promote bone formation represent the next-generation of therapeutic agents for osteo-regenerative medicine."

Fate Therapeutics is utilizing its adult stem cell biology engine and induced pluripotent stem cell (iPSC) technology platform to develop Stem Cell Modulators (SCMs) - small molecules and biologics that guide cell fate for therapeutic purposes. Naturally-occurring adult stem cells, such as mesenchymal stem cells, can differentiate into a variety of cell types and are found in almost all tissues or organs in the body where they are primarily responsible for maintaining and repairing their native tissue. The ability of SCMs to promote bone regeneration may be applied to treat a number of bone injuries and conditions including non-union fracture, spinal fusion or osteoporosis.

The Company's poster entitled, "A small molecule activator of the canonical Wnt pathway stimulates differentiation of mesenchymal stem cells to an osteoblast phenotype," will be presented by Scott Thies, Ph.D., senior director of stem cell biology at Fate Therapeutics, at ISSCR on Friday, July 10 from 4:45 p.m. to 7:00 p.m. CEST.

About Fate Therapeutics, Inc.

Fate Therapeutics is interrogating adult stem cell biology and applying induced pluripotent stem cell (iPSC) technology to develop Stem Cell Modulators (SCMs), small molecule or biologic compounds that guide cell fate for therapeutic purposes. Fate's approach has broad therapeutic potential in areas such as regenerative medicine, hematological diseases, metastatic cancer, traumatic injury and degenerative diseases. The Company is currently conducting a Phase 1b clinical trial of FT1050, a small molecule SCM designed to increase hematopoietic stem cell number and function in dual umbilical cord blood transplant recipients with hematologic malignancies. In addition, Fate Therapeutics and Stemgent have formed an alliance - CATALYST - a collaborative program to provide its members with first access to the most advanced iPSC technologies for drug discovery and development. Fate Therapeutics is headquartered in La Jolla, CA. For more information, please visit

SOURCE Fate Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Prime Therapeutics Receives TIPPS Certification
2. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
3. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
4. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
5. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
6. Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
7. Adams Respiratory Therapeutics Announces FDA Approval of Grape-Flavored Delsym(R)
8. Prime Therapeutics Announces URAC Accreditation
9. Cell Therapeutics, Inc. (CTI) to Present at BIO Investor Forum
10. Horizon Therapeutics, Inc. Scheduled to Present at Upcoming BioPartnering Europe Meeting
11. Sontra Medical Corporation Changes Name to Echo Therapeutics, Inc.
Post Your Comments:
(Date:11/25/2015)... Indianapolis, IN (PRWEB) , ... November 25, 2015 ... ... clean water accessible for all, Water For Empowerment ™ attracts volunteers together ... on clean water by empowering women as key stakeholders in the process. The ...
(Date:11/25/2015)... Cokato, MN (PRWEB) , ... November 25, 2015 , ... ... Thanksgiving through Christmas Eve on several models of traditional and far-infrared saunas. ... . Nordic Spruce is the most traditional Finnish sauna wood, and Finnleo uses only ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... direct sauna parts and accessories. , Sauna accessories help improve the bather experience ... and personality. From basic styles for the purist looking for simplicity in design ...
(Date:11/25/2015)... ... November 26, 2015 , ... ... (AUC), European Union (EU), ANDI Pan African Centres of Excellence, and public R&D ... Nairobi (UNON) for the opening of the 5th African Network for Drugs and ...
(Date:11/25/2015)... ... , ... For the first time, Vitalalert is donating half of its earnings ... partnership between the two groups began in 2014 with Vitalalert pledging a portion of ... was founded in 1954 and is an international Christian-based health organization whose mission is ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... --> --> ... The potential to save costs, improve treatment quality and ... fully exploited as yet. Here, particular emphasis is placed ... mobile tablet or directly at the patients, bedside. ... ) -->      (Photo: ...
(Date:11/27/2015)... Research and Markets ( ) has announced the ... report to their offering. ... author the present scenario and growth prospects of the ... market size, the report considers revenue generated from the ... copper IUDs. The report forecasts the global intrauterine devices ...
(Date:11/26/2015)... Bajos, November 26, 2015 Un ... de Bremachlorin para el cáncer avanzado.   ... la terapia fotodinámica de Bremachlorin para el cáncer avanzado. ... combina la inmunoterapia con la terapia fotodinámica de Bremachlorin ... Cancer Research . --> Clinical Cancer Research ...
Breaking Medicine Technology: